ADC Therapeutics SA (ADCT)

Name: ADC Therapeutics SA (ADCT) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001771910 · NYSE · Pharmaceutical Preparations

Sector Manufacturing
Fiscal year ends Dec 31

For the year ended 2025-12-31, ADC Therapeutics SA reported revenue of $81.36M. Revenue grew 14.9% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $79.58M.

Key ratios (year ended 2025-12-31)

92.9%

Gross margin (computed)

-149.3%

Operating margin

-175.3%

Net margin

14.9%

Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-13

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue	$79.58M	$81.36M	$70.84M	$69.56M	$209.91M
Cost of Revenue	n/a	$5.80M	$5.95M	$2.53M	$3.30M
Gross Profit (computed)	n/a	$75.56M	$64.89M	n/a	n/a
R&D Expense	$82.23M	$104.00M	$109.63M	$127.13M	$186.46M
Operating Income	-$99.55M	-$121.50M	-$130.65M	-$165.99M	-$123.34M
Net Income	-$96.91M	-$142.62M	-$157.85M	-$240.05M	-$157.13M
EPS (Diluted)	n/a	-$1.12	-$1.62	-$2.94	-$2.01
Total Assets	$279.38M	$323.15M	$321.98M	$354.78M	$490.86M
Total Liabilities	$507.58M	$508.98M	$524.62M	$503.03M	$411.41M
Shareholders' Equity	-$228.21M	-$185.83M	-$202.64M	-$148.25M	$79.45M
Cash & Equivalents	$219.11M	$261.34M	$250.87M	$278.60M	$326.44M
Operating Cash Flow	-$102.27M	-$141.17M	-$123.83M	-$118.69M	-$138.31M
Capital Expenditures	$32.0K	$264.0K	$867.0K	$3.22M	$687.0K
Free Cash Flow	-$102.30M	-$141.44M	-$124.70M	-$121.90M	-$139.00M
Shares Outstanding	127.44M	125.75M	98.86M	82.29M	80.64M
Weighted Average Diluted Shares	n/a	127.07M	97.16M	81.71M	78.15M
EPS (Basic)	n/a	-$1.12	-$1.62	-$2.94	-$2.01

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView